Eikon Therapeutics, Inc.
A biotech company that watches individual protein molecules move inside living cells to hunt for cancer drugs, running clinical trials for an immunotherapy against melanoma and lung cancer as well as PARP inhibitors for other tumor types. Founded in 2019 by scientists including a Nobel Prize winner, it took its name from the Greek word for "image," a nod to the microscopy that lets it watch proteins in action.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| FMR LLC | 13G/APassive | 9.2% | 4.99M | Aug 6, 2026 |
| Abigail P. Johnson | 13G/APassive | 9.2% | 4.99M | Aug 6, 2026 |
| Innovation Endeavors III LP | 13GPassive | 5% | 2.72M | May 15, 2026 |
| Innovation Endeavors III GP, LLC | 13GPassive | 5% | 2.72M | May 15, 2026 |
| Innovation Endeavors IV LP | 13GPassive | 0.9% | 498.5K | May 15, 2026 |
| Innovation Endeavors IV GP, LLC | 13GPassive | 0.9% | 498.5K | May 15, 2026 |
| Innovation Endeavors ET SPV LP | 13GPassive | 0.3% | 147.8K | May 15, 2026 |
| Innovation Endeavors ET SPV GP LLC | 13GPassive | 0.3% | 147.8K | May 15, 2026 |
| PERLMUTTER ROGER M | 13GPassive | 5.2% | 2.89M | May 13, 2026 |
| BlackRock Portfolio Management LLC | 13GPassive | 5.5% | 3.00M | Apr 29, 2026 |